Method
Level · gp.fundamentals.debt_to_revenue
Raw value 57390.66% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTBioXcel Therapeutics, Inc.'s latest supported as-filed period reports revenue of $182,000. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.debt_to_revenue
Raw value 57390.66% · OPTIONAL
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.00% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -3350.55% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 51.67% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 265.38% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 87.91% · CORE
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 3 independently calculated changes: Revenue increased 51.7%; Operating margin moved 760945 bp higher; Operating income increased 35.7%.
3 evidence-backed componentsCurrent liabilities changed +310.9% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
BTAI · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001104659-26-104106SEC ↗8-KAug 28, 2026Period Aug 27, 20260001104659-26-102570SEC ↗8-KAug 25, 2026Period Aug 24, 20260001104659-26-100532SEC ↗8-KAug 24, 2026Period Aug 21, 20260001104659-26-099900SEC ↗4Aug 14, 2026Period Aug 12, 20260001104659-26-097388SEC ↗10-QAug 13, 2026Period Jun 30, 20260001104659-26-095965SEC ↗8-KAug 11, 2026Period Aug 10, 20260001104659-26-093710SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 12, 2026Filed Aug 14, 2026 | Atkins Susan E.Director | Grant Or AwardDirect | 17,000 | $0 | $0 | Form 4 ↗ |
| Jun 15, 2026Filed Jun 17, 2026 | Rodriguez JavierSee Remarks | Option ExerciseDirect | 35 | — | — | Form 4 ↗ |
| Jun 15, 2026Filed Jun 17, 2026 | Rodriguez JavierSee Remarks | Option ExerciseDirect | 35 | $0 | $0 | Form 4 ↗ |
| Jun 15, 2026Filed Jun 17, 2026 | Steinhart Richard IChief Financial Officer | Option ExerciseDirect | 35 | — | — | Form 4 ↗ |
| Jun 15, 2026Filed Jun 17, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Level · gp.fundamentals.operating_margin
Raw value -5600.55% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 1738.46% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 196.70% · OPTIONAL
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Noncurrent long-term debt changed -100.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Current ratio changed -72.3% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Working capital / assets changed -34504 basis points from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Operating income changed +35.7% from the comparable as-filed period.
Operating cash flow changed +51.5% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Shares outstanding changed +115.1% from the comparable as-filed period. The change ranks at the 71th percentile of 7 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001104659-26-089436| Steinhart Richard IChief Financial Officer |
| Option ExerciseDirect |
| 35 |
| $0 |
| $0 |
| Form 4 ↗ |
| Jun 15, 2026Filed Jun 17, 2026 | Yocca FrankChief Scientific Officer | Option ExerciseDirect | 35 | — | — | Form 4 ↗ |
| Jun 15, 2026Filed Jun 17, 2026 | Yocca FrankChief Scientific Officer | Option ExerciseDirect | 35 | $0 | $0 | Form 4 ↗ |
| Jun 15, 2026Filed Jun 17, 2026 | Mehta VimalCEO and President | Option ExerciseDirect | 219 | — | — | Form 4 ↗ |
| Jun 15, 2026Filed Jun 17, 2026 | Mehta VimalCEO and President | Option ExerciseDirect | 219 | $0 | $0 | Form 4 ↗ |
| May 20, 2026Filed May 22, 2026 | Rodriguez JavierSee Remarks | Open Market SaleDirect | 6,560 | $1 | $7,111 | Form 4 ↗ |
| May 20, 2026Filed May 22, 2026 | Yocca FrankChief Scientific Officer | Open Market SaleDirect | 6,845 | $1 | $7,427 | Form 4 ↗ |
| May 20, 2026Filed May 22, 2026 | Steinhart Richard IChief Financial Officer | Open Market SaleDirect | 6,845 | $1 | $7,427 | Form 4 ↗ |
| May 20, 2026Filed May 22, 2026 | Mehta VimalCEO and President | Open Market SaleDirect | 19,419 | $1 | $21,108 | Form 4 ↗ |
| May 4, 2026Filed May 22, 2026 | Rodriguez JavierSee Remarks | Option ExerciseDirect | 17,500 | — | — | Form 4 ↗ |
| May 4, 2026Filed May 22, 2026 | Rodriguez JavierSee Remarks | Option ExerciseDirect | 17,500 | $0 | $0 | Form 4 ↗ |
| May 4, 2026Filed May 22, 2026 | Steinhart Richard IChief Financial Officer | Option ExerciseDirect | 17,500 | — | — | Form 4 ↗ |
| May 4, 2026Filed May 22, 2026 | Steinhart Richard IChief Financial Officer | Option ExerciseDirect | 17,500 | $0 | $0 | Form 4 ↗ |
| May 4, 2026Filed May 22, 2026 | Mehta VimalCEO and President | Option ExerciseDirect | 49,758 | — | — | Form 4 ↗ |
| May 4, 2026Filed May 22, 2026 | Mehta VimalCEO and President | Option ExerciseDirect | 49,758 | $0 | $0 | Form 4 ↗ |
| May 4, 2026Filed May 22, 2026 | Yocca FrankChief Scientific Officer | Option ExerciseDirect | 17,500 | $0 | $0 | Form 4 ↗ |